These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6360474)

  • 21. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice.
    Pauwels EK; Stokkel MP
    Q J Nucl Med; 2001 Mar; 45(1):18-26. PubMed ID: 11456371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomes as carriers of imaging agents.
    Caride VJ
    Crit Rev Ther Drug Carrier Syst; 1985; 1(2):121-53. PubMed ID: 3913524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
    Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
    Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of magnetic resonance imaging and 99mTechnetium-labelled methylene diphosphonate bone scintigraphy in the initial assessment of chronic non-bacterial osteomyelitis of childhood and adolescents.
    Morbach H; Schneider P; Schwarz T; Hofmann C; Raab P; Neubauer H; Düren C; Beer M; Girschick HJ
    Clin Exp Rheumatol; 2012; 30(4):578-82. PubMed ID: 22765947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperparathyroidism: comparison of MR imaging with radionuclide scanning.
    Peck WW; Higgins CB; Fisher MR; Ling M; Okerlund MD; Clark OH
    Radiology; 1987 May; 163(2):415-20. PubMed ID: 3562820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic mastocytosis: bone marrow involvement assessed by Tc-99m MDP scintigraphy and magnetic resonance imaging.
    Di Leo C; Lodi A; Pozzato C; Bestetti A; Failoni S; Tagliabue L; Cornalba GP; Tarolo GL
    Haematologica; 2003 Jul; 88(7):ECR26. PubMed ID: 12857573
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical usefulness of thallium-201 scintigraphy and magnetic resonance imaging in the diagnosis of chondromyxoid fibroma.
    Murata H; Horie N; Matsui T; Akai T; Ueda H; Oshima Y; Konishi E; Kubo T
    Ann Nucl Med; 2008 Apr; 22(3):221-4. PubMed ID: 18498038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic imaging techniques in the evaluation of drug-induced pulmonary disease.
    Taylor CR
    Clin Chest Med; 1990 Mar; 11(1):87-94. PubMed ID: 2182281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear medicine techniques and magnetic resonance imaging in coronary artery disease.
    Pauwels E; De Roos A
    Q J Nucl Med; 1996 Mar; 40(1):132-41. PubMed ID: 8681006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Symposium: New methods of research in clinical pharmacology. Paris, 19-20 March 1987. Abstracts].
    Therapie; 1987; Suppl():81-165. PubMed ID: 3495046
    [No Abstract]   [Full Text] [Related]  

  • 32. Nuclear magnetic resonance imaging of liver hemangiomas.
    Sigal R; Lanir A; Atlan H; Naschitz JE; Simon JS; Enat R; Front D; Israel O; Chisin R; Krausz Y
    J Nucl Med; 1985 Oct; 26(10):1117-22. PubMed ID: 3900307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Committee of the German Society for Nuclear Medicine. Clinical quality control of in-vivo studies in nuclear medicine. 1. Recommendations].
    Nuklearmedizin; 1989 Aug; 28(4):suppl 1-32. PubMed ID: 2780328
    [No Abstract]   [Full Text] [Related]  

  • 34. Magnetic resonance imaging (MRI) and technetium-99m-methoxyisonitrile (MIBI) scintigraphy to evaluate the abnormal parathyroid gland and PEIT efficacy for secondary hyperparathyroidism.
    Wada A; Sugihara M; Sugimura K; Kuroda H
    Radiat Med; 1999; 17(4):275-82. PubMed ID: 10510900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear imaging for cardiac amyloidosis.
    Noordzij W; Glaudemans AW; Longhi S; Slart RH; Lorenzini M; Hazenberg BP; Rapezzi C
    Heart Fail Rev; 2015 Mar; 20(2):145-54. PubMed ID: 25424887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of myocardial viability.
    Travin MI; Bergmann SR
    Semin Nucl Med; 2005 Jan; 35(1):2-16. PubMed ID: 15645391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship of nuclear magnetic resonance to nuclear medicine: friend or foe?
    MacIntyre WJ
    J Nucl Med; 1985 Aug; 26(8):958-60. PubMed ID: 4032038
    [No Abstract]   [Full Text] [Related]  

  • 38. Bioengineered Magnetoferritin Nanoprobes for Single-Dose Nuclear-Magnetic Resonance Tumor Imaging.
    Zhao Y; Liang M; Li X; Fan K; Xiao J; Li Y; Shi H; Wang F; Choi HS; Cheng D; Yan X
    ACS Nano; 2016 Apr; 10(4):4184-91. PubMed ID: 26959856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic imaging: developing new roles.
    Henderson BJ
    Can Med Assoc J; 1981 Feb; 124(3):314-20. PubMed ID: 7006788
    [No Abstract]   [Full Text] [Related]  

  • 40. [Principles and developmental status of scintigraphy and nuclear magnetic resonance tomography].
    Bauer R
    Z Kardiol; 1989; 78 Suppl 7():81-96. PubMed ID: 2696261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.